Over the last several years, physicians have been applying energy for skin tightening and other aesthetic corrections; yet, most devices still lack real-time feedback features that intelligently react to how much of that energy is reaching intended tissue targets. One manufacturer has dramatically raised the technology bar, giving physicians automated, intelligent guidance leading to better outcomes.
Multispecialty stem-cell task force recommends facility accreditation and licensure of clinics performing any type of stem-cell treatment
NEW YORK, March 12, 2019 /PRNewswire/ – A recent article published in the Aesthetic Surgery Journal, the clinical, peer-reviewed journal of the American Society for Aesthetic Plastic Surgery (ASAPS/The Aesthetic Society) is calling for the FDA to expedite its oversight of companies and clinics offering stem-cell products and therapies.
Evolus (DWP-450; prabotulinumtoxinA) and Bonti (EB-001A; BoNT/E) report positive progress towards commercialization.
The Food and Drug Administration is in the process of evaluating scientific data on the safety of probiotics and postbiotics in cosmetics, said Linda Katz, M.D., director of the Office of Cosmetics and Color for the FDA.
The FDA is seeking permanent injunctions against a stem cell clinic in Florida and one in California to stop marketing stem cell products that lack FDA approval.